JP2018505870A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505870A5
JP2018505870A5 JP2017537397A JP2017537397A JP2018505870A5 JP 2018505870 A5 JP2018505870 A5 JP 2018505870A5 JP 2017537397 A JP2017537397 A JP 2017537397A JP 2017537397 A JP2017537397 A JP 2017537397A JP 2018505870 A5 JP2018505870 A5 JP 2018505870A5
Authority
JP
Japan
Prior art keywords
cell permeable
conjugate
protein
cell
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017537397A
Other languages
English (en)
Japanese (ja)
Other versions
JP7260248B2 (ja
JP2018505870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013668 external-priority patent/WO2016115500A1/en
Publication of JP2018505870A publication Critical patent/JP2018505870A/ja
Publication of JP2018505870A5 publication Critical patent/JP2018505870A5/ja
Priority to JP2021087385A priority Critical patent/JP2021152022A/ja
Application granted granted Critical
Publication of JP7260248B2 publication Critical patent/JP7260248B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017537397A 2015-01-16 2016-01-15 細胞透過性抗体 Active JP7260248B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021087385A JP2021152022A (ja) 2015-01-16 2021-05-25 細胞透過性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562104653P 2015-01-16 2015-01-16
US62/104,653 2015-01-16
PCT/US2016/013668 WO2016115500A1 (en) 2015-01-16 2016-01-15 Cell penetrating antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021087385A Division JP2021152022A (ja) 2015-01-16 2021-05-25 細胞透過性抗体

Publications (3)

Publication Number Publication Date
JP2018505870A JP2018505870A (ja) 2018-03-01
JP2018505870A5 true JP2018505870A5 (https=) 2019-05-23
JP7260248B2 JP7260248B2 (ja) 2023-04-18

Family

ID=56406478

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017537397A Active JP7260248B2 (ja) 2015-01-16 2016-01-15 細胞透過性抗体
JP2021087385A Pending JP2021152022A (ja) 2015-01-16 2021-05-25 細胞透過性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021087385A Pending JP2021152022A (ja) 2015-01-16 2021-05-25 細胞透過性抗体

Country Status (18)

Country Link
US (1) US11730789B2 (https=)
EP (2) EP3795168A1 (https=)
JP (2) JP7260248B2 (https=)
KR (1) KR20170098957A (https=)
CN (2) CN113797349A (https=)
AR (1) AR103428A1 (https=)
AU (2) AU2016206475B2 (https=)
BR (1) BR112017015203A2 (https=)
CA (1) CA2972986A1 (https=)
EA (1) EA201791610A1 (https=)
IL (1) IL253403A0 (https=)
MX (2) MX386621B (https=)
PH (1) PH12017501271A1 (https=)
SG (1) SG11201705413WA (https=)
TW (1) TW201632207A (https=)
UY (1) UY36519A (https=)
WO (1) WO2016115500A1 (https=)
ZA (2) ZA201705120B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206475B2 (en) * 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
JP6752231B2 (ja) 2015-06-01 2020-09-09 カリフォルニア インスティテュート オブ テクノロジー 抗原を用いて特異的集団に関してt細胞をスクリーニングするための組成物および方法
TW201718023A (zh) 2015-08-06 2017-06-01 世代好公司 細胞滲透性蛋白質-抗體結合物及使用方法
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
WO2018165475A1 (en) 2017-03-08 2018-09-13 California Institute Of Technology Pairing antigen specificity of a t cell with t cell receptor sequences
CN111093710A (zh) * 2017-07-13 2020-05-01 希望之城 硫代磷酸酯缀合的肽及其使用方法
WO2019125033A1 (ko) * 2017-12-22 2019-06-27 (주)로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
KR102075724B1 (ko) 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
US20230330246A1 (en) * 2020-05-05 2023-10-19 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
US20230321250A1 (en) * 2020-07-08 2023-10-12 Octagon Therapeutics, Inc. Cancer cell modulators
KR102739776B1 (ko) 2020-10-26 2024-12-09 한국원자력의학원 로자탄을 유효성분으로 포함하는 항암제의 종양 침투력 증진용 조성물 및 이의 용도
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス, インコーポレイテッド γ−インターフェロンに対するヒト化抗体
CA2494508A1 (en) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2007025365A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions
CA2633063A1 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
US20100239504A1 (en) * 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
US20110218334A1 (en) 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
EP2318528A1 (en) 2008-07-24 2011-05-11 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
CN111437395A (zh) * 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
AU2016206475B2 (en) * 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
JP7073109B2 (ja) * 2015-07-02 2022-05-23 シティ・オブ・ホープ ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
WO2017024239A1 (en) * 2015-08-06 2017-02-09 City Of Hope Therapeutic cell internalizing conjugates

Similar Documents

Publication Publication Date Title
JP2018505870A5 (https=)
JP2021152022A5 (https=)
JP2018525381A5 (https=)
CA2783691C (en) Anti-inflammatory agents directed against citrullinated epitopes
JP2021531826A5 (https=)
EP2294086B1 (en) Anti-inflammatory agents
JP2006524986A5 (https=)
WO2015195803A1 (en) Methods and compositions for in vivo non-covalent linking
JP2021167329A5 (https=)
WO2019094395A3 (en) Hydrophilic linkers for antibody drug conjugates
HRP20130877T1 (hr) Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
JP2017113019A5 (https=)
JP2018525001A5 (https=)
JP2010511397A5 (https=)
JP2012139224A5 (https=)
JP2016521683A5 (https=)
RU2010141584A (ru) Антитело против csf-1r
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
WO2008006235A3 (en) Scfv antibodies which pass epithelial and/or endothelial layers
ES2813415T3 (es) Métodos y composiciones para el tratamiento de enfermedades autoinmunes e inflamatorias
JP2014518883A5 (https=)
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
CN110325188A (zh) 小分子蛋白质精氨酸甲基转移酶5(prmt5)抑制剂和治疗方法
JP2013535190A5 (https=)
US10456466B2 (en) Anti-VEGF antibody